222 related articles for article (PubMed ID: 27702824)
41. TP53 mutation analysis of malignant peripheral nerve sheath tumors.
Verdijk RM; den Bakker MA; Dubbink HJ; Hop WC; Dinjens WN; Kros JM
J Neuropathol Exp Neurol; 2010 Jan; 69(1):16-26. PubMed ID: 20010306
[TBL] [Abstract][Full Text] [Related]
42. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
43. Restoration of p53 function in anaplastic Wilms' tumor.
Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP
J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436
[TBL] [Abstract][Full Text] [Related]
44. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
45. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
el Bahtimi R; Hazen-Martin DJ; Re GG; Willingham MC; Garvin AJ
Mod Pathol; 1996 Mar; 9(3):238-44. PubMed ID: 8685221
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
47. Bilateral Wilms tumor and early presentation in pediatric patients is associated with the truncation of the Wilms tumor 1 protein.
Hu M; Fletcher J; McCahon E; Catchpoole D; Zhang GY; Wang YM; Algar EM; Alexander SI
J Pediatr; 2013 Jul; 163(1):224-9. PubMed ID: 23403252
[TBL] [Abstract][Full Text] [Related]
48. Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors.
Treger TD; Chagtai T; Butcher R; Cresswell GD; Al-Saadi R; Brok J; Williams RD; Roberts C; Luscombe NM; Pritchard Jones K; Mifsud W
Transl Oncol; 2018 Dec; 11(6):1301-1306. PubMed ID: 30172241
[TBL] [Abstract][Full Text] [Related]
49. Extrarenal Anaplastic Wilms Tumor: A Case Report With Genomic Analysis and Tumor Models.
Willis KR; Sathe AA; Xing C; Koduru P; Artunduaga M; Butler EB; Park JY; Kurmasheva RT; Houghton PJ; Chen KS; Rakheja D
J Pediatr Hematol Oncol; 2022 May; 44(4):147-154. PubMed ID: 35129140
[TBL] [Abstract][Full Text] [Related]
50. The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.
Shenoy A; Alvarez E; Chi YY; Li M; Shern JF; Khan J; Hiniker SM; Granberg CF; Hawkins DS; Parham DM; Teot LA; Rudzinski ER
Eur J Cancer; 2021 Jan; 143():127-133. PubMed ID: 33302115
[TBL] [Abstract][Full Text] [Related]
51. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
52. Mutations of p53 in Wilms' tumors.
Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
[TBL] [Abstract][Full Text] [Related]
53. New developments in the pathology of Wilms tumor.
Beckwith JB
Cancer Invest; 1997; 15(2):153-62. PubMed ID: 9095211
[TBL] [Abstract][Full Text] [Related]
54. A gene expression signature for relapse of primary wilms tumors.
Li W; Kessler P; Yeger H; Alami J; Reeve AE; Heathcott R; Skeen J; Williams BR
Cancer Res; 2005 Apr; 65(7):2592-601. PubMed ID: 15805255
[TBL] [Abstract][Full Text] [Related]
55. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
56.
Liu P; Zhuo Z; Li W; Cheng J; Zhou H; He J; Zhang J; Wang J
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30610160
[TBL] [Abstract][Full Text] [Related]
57. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia.
Li W; Kessler P; Williams BR
Oncogene; 2005 Jan; 24(3):457-68. PubMed ID: 15531917
[TBL] [Abstract][Full Text] [Related]
58. Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1.
Lehnhardt A; Karnatz C; Ahlenstiel-Grunow T; Benz K; Benz MR; Budde K; Büscher AK; Fehr T; Feldkötter M; Graf N; Höcker B; Jungraithmayr T; Klaus G; Koehler B; Konrad M; Kranz B; Montoya CR; Müller D; Neuhaus TJ; Oh J; Pape L; Pohl M; Royer-Pokora B; Querfeld U; Schneppenheim R; Staude H; Spartà G; Timmermann K; Wilkening F; Wygoda S; Bergmann C; Kemper MJ
Clin J Am Soc Nephrol; 2015 May; 10(5):825-31. PubMed ID: 25818337
[TBL] [Abstract][Full Text] [Related]
59. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
60. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
